Advanced Hodgkin Lymphoma: A Regimen That Risks His Lungs, and One That Risks His Hands
A 29-year-old guitarist with advanced Hodgkin lymphoma, choosing between a regimen that threatens his lungs and one that threatens his hands. Only one of those two organs has actually been measured.
N.R., a 29-year-old man, splits his week between managing inventory at a hardware store and playing guitar most weekend nights with a local cover band that has, by his own account, finally started drawing a real crowd. A biopsy of a persistent neck mass, initially attributed to a lingering cold, returned classical Hodgkin lymphoma, nodular sclerosing subtype, and staging scans confirmed advanced-stage disease with bulky mediastinal involvement. He has had mild intermittent asthma since childhood, controlled on an as-needed albuterol inhaler he reaches for perhaps twice a month, and he has never had formal pulmonary function testing — so the word "mild" in his chart is a history, not a measurement. His baseline neurologic exam, by contrast, has been done and is clean: no pre-existing neuropathy, normal fine motor function in both hands.
Each of the two standard first-line regimens for advanced disease charges him in a different currency. ABVD carries bleomycin, whose pulmonary toxicity is well documented and occasionally fatal, and reactive airway disease — even the mild kind — is the sort of baseline that turns an average risk into an elevated one, though nobody can say by how much without the spirometry he has never had. Brentuximab vedotin plus AVD, which ECHELON-1 showed improves progression-free survival, deletes bleomycin outright, and charges him instead in peripheral neuropathy, landing on the fingers a semi-professional guitarist uses for a second income and, by his own description, for something closer to an identity. The asymmetry that decides this is not in the two toxicity rates. It is that one of these risks has been objectively characterized in him and the other has been assumed from a childhood diagnosis and an inhaler he barely uses.
Lymphoma clinic, regimen selection
ECHELON-1 showed a real progression-free survival advantage for brentuximab vedotin plus AVD over ABVD in advanced-stage disease, and it removes bleomycin entirely — a genuinely important consideration given his existing reactive airway disease, since bleomycin pulmonary toxicity in a patient with baseline airway compromise is a real, sometimes fatal risk I'd rather not accept if there's an equally effective alternative.
I'd weigh his hands just as seriously as his lungs. Brentuximab's peripheral neuropathy is real, and while it's often reversible, it isn't always fully so — and for a working guitarist, partial reversibility isn't a small caveat. RATHL's PET-adapted protocol offers a genuine third path: start ABVD, and if his interim PET is negative after two cycles, drop bleomycin from the remaining cycles entirely. That could meaningfully reduce his actual bleomycin exposure without ever putting brentuximab's neuropathy risk on the table.
Removing bleomycin from the regimen isn't the only way to reduce his exposure to it — RATHL already validated a way to do that within ABVD itself, for exactly the patients who respond well early.
Before either path is finalized, I'd want his actual baseline pulmonary function measured, not just his history of mild, well-controlled symptoms. A formal PFT would tell us whether his reactive airway disease is truly mild in objective terms or whether it's been under-recognized — and that changes how much of the bleomycin risk in RATHL's approach is actually his to weigh, versus how much is being estimated from a childhood diagnosis and an inhaler he barely uses.
Agreed: start ABVD with baseline pulmonary function confirmed normal, planning to drop bleomycin after cycle 2 if interim PET is negative per the RATHL protocol.
Not settled today, only deferred to a specific future checkpoint: if his interim PET after cycle 2 doesn't clear, the plan converts automatically to brentuximab vedotin plus AVD, ECHELON-1's overall efficacy edge notwithstanding — and the team agreed in advance that his airway history alone won't be grounds to keep him on continued bleomycin exposure once that trigger is met.